Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016
Our recent RWE study detailed the comorbidity burden of Finnish multiple myeloma (MM) patients diagnosed between 2005 and 2016.
Latest News
Current topics from the world of pharmaceuticals, healthcare and research. Make sure to also check out our RWE-themed blog!
Latest articles
-
-
Text mining helped analyse a million entries on smoking
How to review and analyse a million sentences? Text mining decreased the work of clinical experts and accelerated the research process.
-
Heini Honkanen appointed as Medaffcon’s Market Access Lead
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
-
Terveyttä datasta RWE provides information for many needs
Real-world evidence (RWE) studies are usually started with a specific use for results in mind. However, the amount and significance of the evidence generated in the RWE studies become clearer during the project. The results of the RWE studies are usually much more versatile than one could have dreamed of at the beginning of the project.</p>
-
Unstructured healthcare data contributes to solving new issues
Finland has unique data for pharmaceutical purposes and unstructured healthcare data can also be already effectively utilised.
-
Greetings from ISPOR: the use of Real World Evidence is becoming more common
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
Most popular articles
-
Finnish ecosystem supports the use of real world evidence (RWE)
Real World Evidence (RWE) ecosystem in Finland Real world data (RWD) is defined by FDA…
-
Pharmaceutical Pricing and Market Access of Medicine products in Finland
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes…
-
Navigating the Real World Data (RWD) landscape in Finland
The real world data (RWD) landscape in Finland offers globally unique data and possibilities to…
-
Finnish pricing and reimbursement landscape
Pricing and reimbursement in Finland Pharmaceuticals Pricing Board (PPB), operating under the Ministry of Social…
-
Real world evidence (RWE) supported health technology assessment (HTA)
Demonstrating that a health technology, e.g. a product, procedure or any intervention, is worth its…
-
Possibilities of machine learning and artificial intelligence in RWE studies
Currently huge piles of health care data have been collected in Finland through national, regional…
Health from Data-blog
- Terveyttä datasta
RWE provides information for many needs
Real-world evidence (RWE) studies are usually started with a specific use for results in mind. However, the amount and significance of the evidence generated in the RWE studies become clearer during the project. The results of the RWE studies are usually much more versatile than one could have dreamed of at the beginning of the project.</p>
-
Terveyttä datasta World of methodologies | Virtual control arms provide more data for decision making
Recently, there has been a lot of discussion on virtual control arms. In this blog post Data Scientist and virtual control arm specialist Johanna Vikkula explains how virtual control arm can be formed using Real-World data (RWD) and why to use virtual control arms.</p>
-
Terveyttä datasta Enjoy your summer vacation and come back fast – Interesting RWE to be published this year
Last summer the readers of my blog guessed that the number of real-world evidence (RWE) studies published during the year (2021) would be about 1,500 pcs. Currently, the PubMed database covers 1,290 published RWE studies in 2021 (on June 1st, 2022, searching with the words "real world evidence").
-
Terveyttä datasta Safety from Data | How patient register data can add to the safety and effectiveness of pharmacotherapy
The safety and efficacy of pharmacotherapy can be measured in multiple ways during the different stages of a drug’s life cycle. Adverse drug reactions and medication errors are described in the data stored in the health care registers, enabling the retrospective research of the events. Research focusing on medication safety forms the basis for the effectiveness of individual therapies. This post starts a new series of featuring blog posts, called Safety from data. The writer of this post, Outi Laatikainen, works as a Scientific Advisor at Medaffcon and has vast previous experience in medication safety research in specialized health care.</p>
-
Terveyttä datasta Registry data to support clinical trials
Randomized clinical trials (RCT) have traditionally been held up as the gold standard for studying the efficacy of a treatment. Recently, real-world evidence (RWE) has been pushed alongside the RCT. Both of the methods above have their strengths, which is why RCT and RWE have their place in the life cycle of a drug. Those who utilize both RCT and RWE are surfing on the wave's crest.</p>
-
Terveyttä datasta World of methodologies | Unstructured data and Machine learning in Real-World Evidence studies
We start this year in the world of methodologies with a hot topic of utilizing unstructured data in the generation of real-world evidence (RWE). This blogging is authored by Medaffcon‘s Junior Data Scientist Olivia Hölsä who has expertise in text mining and machine learning. In this post, we enter into special characteristics of unstructured data and more specifically into real-world text data. </p>